Act-HIB

Haemophilus influenzae type b infection, (meningitis, septicemia, cellulitis, arthritis).

Vaccine is administered as a single dose (0.5 mL) by intramuscular injection into the anterolateral aspect of the thigh or deltoid.

H. influenzae Type B Immunization Prevention of invasive disease caused by Haemophilus influenzae type b. (Vaccine is approved for use in children 2 months through 5 years of age) A 4-dose series (0.5 mL each) given by intramuscular injection (2.3): • Primary series: One dose each at 2, 4, and 6 months of age. The first dose may be given as early as 6 weeks of age. • Booster: One dose at 15 through 18 months of age. Infants between the ages of 6 and 12 months previously unvaccinated should receive 2 injections, given with an interval of one month, followed by a booster in the second year of life. Children aged 1-5 years who were previously not vaccinated should be given one dose of the vaccine.

Hypersensitivity

Antigenic capsular polysaccharides induce Ab production.

Minor illnesses such as upper respiratory infection with or without low-grade fever are not contraindications for use of HIB vaccine. As reported with Haemophilus b polysaccharide vaccines, cases of H influenzae type b disease may occur subsequent to vaccination and prior to the onset of protective effects of the vaccine. Medical supervision is needed. Lactation: Excretion in milk unknown

Irritability (72.6%), drowsiness (57.5%), tenderness (46.3%), induration (22.5%), fever (20.1%), anorexia (15.3%), diarrhea (4.4%) Frequency Not Defined Pain,Sleepiness,Rash,Vomiting Injection site erythema/induration/pain/soreness/warmth/swelling Otitis media,URI

Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses) may reduce the immune response to vaccine.